Cocaine Dependence Clinical Trial
Official title:
Cognitive-enhancing DA Medications for Cocaine Dependence
| Verified date | March 2018 |
| Source | The University of Texas Health Science Center, Houston |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to evaluate treatments designed to improve cocaine treatment success by combining medications that target cocaine-related cognitive impairments.
| Status | Completed |
| Enrollment | 119 |
| Est. completion date | February 2017 |
| Est. primary completion date | February 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 55 Years |
| Eligibility |
Inclusion Criteria: - meet criteria for cocaine dependence - seeking treatment for cocaine dependence - be in acceptable health based on medical history and physical exam Exclusion Criteria: - dependent on drugs other than cocaine, nicotine, marijuana - have a medical condition contraindicating treatment with study medications - having conditions of probation or parole requiring reports of drug use to officers of the court |
| Country | Name | City | State |
|---|---|---|---|
| United States | Behavioral and Biomedical Sciences Building | Houston | Texas |
| Lead Sponsor | Collaborator |
|---|---|
| The University of Texas Health Science Center, Houston |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Cocaine Use Based on Urine Drug Screening | The mean of the predicted probabilities (derived from generalized linear mixed models) of negative drug screens over all 10 weeks is reported, as per the analysis proposed in the protocol. | 10 weeks | |
| Secondary | Number of Participants Who Completed the 10 Week Trial | 10 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04994821 -
tDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study
|
Phase 2 | |
| Completed |
NCT01601743 -
Exercise as a Behavioral Treatment for Cocaine Dependence
|
N/A | |
| Completed |
NCT01402492 -
Cocaine Use Reduction With Buprenorphine
|
Phase 2/Phase 3 | |
| Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
| Completed |
NCT00880997 -
The Efficacy of Doxazosin for Cocaine Users
|
Phase 1 | |
| Completed |
NCT00566969 -
Cocaine Withdrawal and Pharmacotherapy Response
|
N/A | |
| Completed |
NCT00585520 -
Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues
|
Phase 1 | |
| Completed |
NCT00368290 -
Modafinil Treatment for Cocaine Dependence and HIV High-Risk Behavior
|
Phase 2 | |
| Completed |
NCT00322309 -
Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects
|
Phase 2 | |
| Completed |
NCT00385801 -
Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence
|
Phase 2 | |
| Completed |
NCT00167245 -
Topiramate for Alcohol and Cocaine Dependence
|
Phase 2 | |
| Completed |
NCT00842517 -
Long Term Maintenance of Drug Abstinence
|
Phase 1 | |
| Not yet recruiting |
NCT05974202 -
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
|
Phase 2 | |
| Completed |
NCT04411914 -
Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid
|
Phase 1 | |
| Active, not recruiting |
NCT03266939 -
Rebalancing the Serotonergic System in Cocaine Dependence
|
Phase 1 | |
| Completed |
NCT02563769 -
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
|
Phase 1 | |
| Recruiting |
NCT06159387 -
Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts
|
Phase 4 | |
| Terminated |
NCT02935101 -
Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants
|
Phase 2 | |
| Completed |
NCT02018263 -
Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans
|
Phase 1 | |
| Completed |
NCT01573273 -
Oxytocin in Cocaine Dependence
|
N/A |